Sommaire

Numéro précédent | Numéro suivant

• • ·Oncologists in social media—what are the limits?

    Page :553

     
• • ·Should tomosynthesis replace mammography for breast cancer screening?

    Page :554-555

    Nehmat Houssami

     
• • ·Is tailored systemic therapy in renal cell carcinoma realistic?

    Page :555-557

    Tsunenori Kondo

     
• • ·Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer

    Page :557-558

    Stanislas Quesada, William Jacot

     
• • ·Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer

    Page :558-560

    Juanita Crook

     
• • ·Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction

    Page :560-562

    Orit Kaidar-Person, Philip Poortmans

     
• • ·War-torn Afghanistan and cancer care: where to focus?

    Page :562-563

    Usman Ayub Awan, Muhammad Wasif Malik, Muhammad Sohail Afzal, Haroon Ahmed, Sarmad Zahoor

     
• • ·The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint

    Page :563-566

    Nicholas C Richardson, Yvette Kasamon, Richard Pazdur, Nicole Gormley

    
• • ·Re-engaging EU citizens with national screening programmes and cancer diagnosis post-pandemic

    Page :566-567

    Anne-Marie Baird

     
• • ·Bridging the equity gap in patient education: the biliary tract cancer BABEL project

    Page :568-570

    Raffaella Casolino, Chiara Braconi, the BABEL working group of the COST Action 18122 (EURO-CHOLANGIO-NET), part of the European Network for the Study of Cholangiocarcinoma, MG Prete, F González Romero, RE Castro, JM Banales, V Cardinale, H Morement, J Milne, M Krawczyk, L Krupa, MM Anwar, ES Poles, V Merz, T Perra, A Porcu, V Megdanova, Y Popova, MI Meneses-Medina, AL Reyes Mondragón, A Burguete-Torres, I Brandão Rego, J Magalhães, J Liz Pimenta, J Silva, M João Sousa, S Custódio, T Costa, FD Cojocaru, VL Drug, SU Hassan, NU Ain Azam, J Kupcinskas, E Kreivenaite, E Morkunas, O Nikolaieva, D Calvisi, M Evert, N Terhuja, A Das, KD Hoang, HH Nguyen, V Evseev, N Khuntikeo, O Abdihamid, E Mariamidze, K Tsiklauri, VPB Koyyala, P Medisetty, L Digumarti, RR Digumarti, VLA Konkalla, S Mitra, R Sud, P Parikh, SK Gupta, S Sen, S Chanda, D das, K Domadia, P Goyal, S Goyal, N Dhamne, PV Acharya, P Jain, M Sharma, GA War, SR Singh, C Dodagoudar, RS Patnaik, SS Mashahary, R Paul, T Kannan, V Goel, N Patnaik, A Jajodia, S Pasricha, M Gupta, C Agarwal, DK Mondal, A BP, S Joga, SK Mullapally, P Choudhary, R Saini, T Selvaraju, S Pahwa, G Durga, U Maheshwari, S Dhaka, S Lindsay, A Omar, A La Casta Muñoa

      
• • ·Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431

    Page :570-572

    Etan Orgel, Doojduen Villaluna, Mark D Krailo, Adam Esbenshade, Lillian Sung, David R Freyer

     
• • ·Patient-reported outcomes: what really matters to patients?

    Page :e198

    Elshad Hasanov, Jaime O Herrera Caceres, Deborah A Maskens, Rachel H Giles, Andreas M Schmitt

     
• • ·Patient-reported outcomes: what really matters to patients? – Authors’ reply

    Page :e199

    David Cella, Toni K Choueiri, Robert J Motzer

    
• • ·Screening for breast cancer brain metastases

    Page :e200

    Jonathan Knisely

    
• • ·Screening for breast cancer brain metastases – Authors’ reply

    Page :e201

    Min Yan

    
• • ·The DRUG Access Protocol: access inequality and European harmonisation

    Page :e202

    Tobias B Polak, David G J Cucchi, Joost van Rosmalen, Carin A Uyl-de Groot

    
• • ·The DRUG Access Protocol: access inequality and European harmonisation – Authors’ reply

    Page :e203

    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Laurien J Zeverijn, Emile E Voest

    
• • ·Has Pakistan failed to roll back HPV?

    Page :e204

    Usman Ayub Awan, Aamer Ali Khattak

    
• • ·A biobank perspective on use of tissue samples donated by trial participants

    Page :e205

    Valerie Speirs, Angela Cox, Claude Chelala, Jacqueline A James, Richard A Adams, J Louise Jones

    
• • ·Accelerated approval requirements for lurbinectedin

    Page :e206

    David J Benjamin, Vinay Prasad

    
• • ·Correction to Lancet Oncol 2021; 22: 1250–64

    Page :e207

    
• • ·Ongoing crisis in Ukraine continues to affect cancer care

    Page :573

    Talha Khan Burki

     
• • ·IAEA reviews plan to release treated water from Fukushima

    Page :574

    Manjulika Das

     
• • ·Cancer care crisis in the Palestinian territories

    Page :575

    Manjulika Das

     
• • ·Biden’s proposed investment in cancer research sparks concerns

    Page :576

    Manjulika Das

     
• • ·Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy

    Page :577-578

    Margaret R Karagas, Amy Wang, David C Dorman, Amy L Hall, Jingbo Pi, Consolato M Sergi, Elaine Symanski, Elizabeth M Ward, Victoria H Arrandale, Kenichi Azuma, Eduardo Brambila, Gloria M Calaf, Jason M Fritz, Shoji Fukushima, Joanna M Gaitens, Tom K Grimsrud, Lei Guo, Elsebeth Lynge, Amélia P Marinho-Reis, Melissa A McDiarmid, Daniel R S Middleton, Thomas P Ong, David A Polya, Betzabet Quintanilla-Vega, Georgia K Roberts, Tiina Santonen, Riitta Sauni, Maria J Silva, Pascal Wild, Changwen W Zhang, Qunwei Zhang, Yann Grosse, Lamia Benbrahim-Tallaa, Aline de Conti, Nathan L DeBono, Fatiha El Ghissassi, Federica Madia, Bradley Reisfeld, Leslie T Stayner, Eero Suonio, Susana Viegas, Roland Wedekind, Shukrullah Ahmadi, Heidi Mattock, William M Gwinn, Mary K Schubauer-Berigan

    
• • ·Failure to tackle workforce shortages threatens cancer survival progress in England

    Page :e208

    Emma Wilkinson

     
• • ·Resilience and perseverance under siege: providing cancer care during the invasion of Ukraine

    Page :579-583

    Darya Kizub, Nelya Melnitchouk, Andriy Beznosenko, Galyna Shabat, Solomiia Semeniv, Leticia Nogueira, Patricia J Watson, Kim Berg, Edward J Trapido, Zelde Espinel, James M Shultz

    Plan Plan  
• • ·FDA decisions on new oncological drugs

    Page :583-585

    Guanqiao Li, Yang Liu, Ruyi He, Ling Su, Xiaoyuan Chen

    Plan Plan  
• • ·FDA decisions on new oncological drugs

    Page :585-586

    David J Benjamin, Vinay Prasad, Mark P Lythgoe

    Plan Plan
• • ·Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study

    Page :587-600

    Sean McPhail, Ruth Swann, Shane A Johnson, Matthew E Barclay, Hazem Abd Elkader, Riaz Alvi, Andriana Barisic, Oliver Bucher, Gavin R C Clark, Nicola Creighton, Bolette Danckert, Cheryl A Denny, David W Donnelly, Jeff J Dowden, Norah Finn, Colin R Fox, Sharon Fung, Anna T Gavin, Elba Gomez Navas, Steven Habbous, Jihee Han, Dyfed W Huws, Christopher G C A Jackson, Henry Jensen, Bethany Kaposhi, S Eshwar Kumar, Alana L Little, Shuang Lu, Carol A McClure, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Sabuj Sarker, Luc te Marvelde, Rebecca S Thomas, Robert J S Thomas, Catherine S Thomson, Ryan R Woods, Bin Zhang, Georgios Lyratzopoulos, ICBP Module 9 Emergency Presentations Working Group, Brooke Filsinger, Katharina Forster, Leon May, David S Morrison, A. Ffion Thomas, Janet L Warlow, Hui You

    Résumé Résumé Plan Plan   
• • ·Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial

    Page :601-611

    Walter Heindel, Stefanie Weigel, Joachim Gerß, Hans-Werner Hense, Alexander Sommer, Miriam Krischke, Laura Kerschke, for the TOSYMA Screening Trial Study Group

    Résumé Résumé Plan Plan   
• • ·Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

    Page :612-624

    Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard

    Résumé Résumé Plan Plan   
• • ·De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

    Page :625-635

    Ulrike Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Michael Braun, Doris Augustin, Jochem Potenberg, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck, WSG-ADAPT investigators, Raquel von Schumann, Walther Kuhn, Silke Polata, Wojciech Bielecki, Ralf Meyer, Marianne Just, Susanne Kraudelt, Wulf Siggelkow, Heidi Wortelmann, Anke Kleine-Tebbe, Lena Leitzen, Heidrun Kirchhof, Petra Krabisch, John Hackmann, Reinhard Depenbusch, Karsten Gnauert, Peter Staib, Antje Lehnert, Oliver Hoffmann, Susanne Briest, Christoph Lindner, Volker Heyl, Leila Bauer, Christoph Uleer, Svjetlana Mohrmann, Nicole Viehstaedt, Wolfram Malter, Theresa Link, Nana Buendgen, Joke Tio

    Résumé Résumé Plan Plan   
• • ·Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial

    Page :636-649

    Shigehira Saji, Naruto Taira, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi

    Résumé Résumé Plan Plan   
• • ·Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

    Page :650-658

    Syed A Hussain, Jason F Lester, Richard Jackson, Matthew Gornall, Muneeb Qureshi, Anthony Elliott, Simon J Crabb, Robert A Huddart, Naveen Vasudev, Alison J Birtle, Jane Worlding, Nicholas D James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark D Linch, Irbaz B Riaz, James W F Catto, Thomas Powles, Robert J Jones

    Résumé Résumé Plan Plan   
• • ·Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    Page :659-670

    Luis A Diaz, Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardiere, Fernando Rivera, Elena Elez, Dung T Le, Takayuki Yoshino, Wen Yan Zhong, David Fogelman, Patricia Marinello, Thierry Andre, KEYNOTE-177 Investigators

    Résumé Résumé Plan Plan   
• • ·High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

    Page :671-681

    Almudena Zapatero, Araceli Guerrero, Xavier Maldonado, Ana Álvarez, Carmen González San-Segundo, María Ángeles Cabeza Rodríguez, Josep María Solé, Agustí Pedro Olivé, Francesc Casas, Ana Boladeras, Carmen Martín de Vidales, María Luisa Vázquez de la Torre, Susana Vara, Juan Luis Sanz, Felipe A Calvo

    Résumé Résumé Plan Plan   
• • ·Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study

    Page :682-690

    Paul T R Thiruchelvam, Daniel R Leff, Amy R Godden, Susan Cleator, Simon H Wood, Anna M Kirby, Navid Jallali, Navita Somaiah, Judith E Hunter, Francis P Henry, Aikaterini Micha, Rachel L O’Connell, Kabir Mohammed, Neill Patani, Melissa L H Tan, Dorothy Gujral, Gillian Ross, Stuart E James, Aadil A Khan, Jennifer E Rusby, Dimitri J Hadjiminas, Fiona A MacNeill, PRADA Trial Management Group, Paul TR Thiruchelvam, Daniel R Leff, Amy R Godden, Susan Cleator, Simon H Wood, Anna M Kirby, Navita Somaiah, Neill Patani, Dorothy Gujral, Gillian Ross, Stuart James, Aadil Khan, Jennifer E Rusby, Dimitri Hadjiminas, Fiona A MacNeill

    Résumé Résumé Plan Plan   
• • ·Equity in national cancer control plans in the region of the Americas

    Page :e209

    Patrícia Loggetto, Julie Ritter, Kelsey Marx, Monika L Metzger, Catherine G Lam

    Résumé Résumé Plan Plan   
• • ·Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children’s Oncology Group

    Page :e218

    Giovanni Morana, Dennis Shaw, Shannon M MacDonald, Claire Alapetite, Thankamma Ajithkumar, Aashim Bhatia, Hervé Brisse, Camilo Jaimes, Thomas Czech, Girish Dhall, Jason Fangusaro, Cecile Faure-Conter, Maryam Fouladi, Darren Hargrave, Julie H Harreld, Dipayan Mitra, James C Nicholson, Mark Souweidane, Beate Timmermann, Gabriele Calaminus, Ute Bartels, Brigitte Bison, Matthew J Murray

    Résumé Résumé Plan Plan   
• • ·Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials

    Page :e229

    Mallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, Ting-Yu Chen, Bellinda L King-Kallimanis, Shenghui Tang, Paul G Kluetz

    Résumé Résumé Plan Plan
• • ·G-CSF-induced carotid inflammation

    Page :e235

    Harshabad Singh, Michael H Rosenthal, Brian M Wolpin